Supplemental material
Leukemia & Lymphoma
Volume 65, 2024 - Issue 4
Original Articles
Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison
, 
, , , , , , , & show all
Meletios A. Dimopoulosb Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greecehttps://orcid.org/0000-0001-8990-3254View further author information
https://orcid.org/0000-0001-8990-3254View further author information, Meral Beksacc Ankara University, Ankara, Turkeyhttps://orcid.org/0000-0003-1797-8657View further author information
https://orcid.org/0000-0003-1797-8657View further author information, Xavier Leleud CHU de Poitiers – La Miletrie, INSERM CIC 1402, Poitiers, Francehttps://orcid.org/0000-0002-9822-4170View further author information
https://orcid.org/0000-0002-9822-4170View further author information, , , , , & show all